Making a medicine out of MDMA.
The British journal of psychiatry : the journal of mental science – January 01, 2015
Source: PubMed
Summary
MDMA, once sidelined, is now recognized for its significant therapeutic potential. Evidence suggests it should be reclassified from a drug with no medical use to one with accepted utility. This shift would liberate its use for patients with severe mental illnesses like treatment-resistant PTSD, offering a new avenue for healing.
Abstract
From its first use 3,4,-methylenedioxymethamphetamine (MDMA) has been recognised as a drug with therapeutic potential. Research on its clinical utility stopped when it entered the recreational drug scene but has slowly resurrected in the past decade. Currently there is enough evidence for MDMA to be removed from its Schedule 1 status of 'no medical use' and moved into Schedule 2 (alongside other misused but useful medicines such as heroin and amphetamine). Such a regulatory move would liberate its use as a medicine for patients experiencing severe mental illnesses such as treatment-resistant post-traumatic stress disorder.